Abstract:As a co-receptor for vascular endothelial growth factor-3 (VEGF-3), neuropilin receptor type-2 (NRP-2) plays a central role in lymphangiogenesis and angiogenesis. Recently, mounting data of evidence show that NRP-2 is overexpressed in several human cancers, and its overexpression is often associated with poor prognosis. Therefore, it is necessary for us to develop an affinity reagent for noninvasive imaging of NRP-2 expression because it may be possible to provide early cancer diagnosis, more accurate prognosis, and better treatment planning. Due to their high affinity, and specificity, monoclonal antibodies (mAbs) have been considered attractive candidates for targeted cancer therapy and diagnostics. We recently generated and validated a monoclonal antibody that specifically binds NRP-2 b1b2 domain with no cross-reactivity to NRP-1 b1b2 domain, also known to be overexpressed in a variety of cancers. Here, we developed a single photon emission computed tomography (SPECT) probe for imaging NRP-2-positive tumors. Anti-NRP-2 monoclonal antibodies were prepared by hybridomas and were labeled with iodine-131 by chloramine-T method. The in vitro physicochemical properties of I-131-anti-NRP-2 mAb was determined. Binding affinity and specificity of I-131-anti-NRP-2 mAb to NRP-2 were assessed using human lung adenocarcinoma A549 cells. Biodistribution and SPECT studies were performed in mice bearing A549 tumor xenografts to evaluate the in vivo performance of I-131-anti-NRP-2 mAb. The preparation of anti-NRP-2 mAb was completed successfully by hybridoma with high purity (>95%) and specific for NRP-2 b1b2 domain, but not NRP-1 b1b2 domain. The radiosynthesis of I-131-anti-NRP-2 mAb was completed successfully within 60 min with high labelling efficiency (94.69 +/- 3.63%), and radiochemical purity (98.56 +/- 0.48%). The resulting probe, I-131-anti-NRP-2 mAb displayed excellent stability in PBS solution during 24-72 h. I-131-anti-NRP-2 mAb showed high binding affinity with A549 cells (96.6 +/- 1.44 nM). In vivo biodistribution and SPECT studies demonstrated targeting of A549 glioma xenografts was NRP-2 specific. The tumor uptake was 5.86 +/- 0.27% ID/g at 6 h, and kept at high level of 4.64 +/- 0.82% ID/g at 72 h-post-injection. The tumor to contralateral muscle ratio (T/NT) was 2.08 +/- 0.33 at 6 h, and reached the highest level of 3.83 +/- 0.18 at 72 h after injection. SPECT imaging studies revealed that I-131-anti-NRP-2 mAb could clearly identify A549 tumors with good contrast, especially at 48-72 h after injection. In conclusion, this study demonstrates that I-131-anti-NRP-2 mAb exhibited highly selective uptake in NRP-2-expressing tumors, and may provide a promising SPECT probe for imaging NRP-2 positive tumors.

EphB4-targeted Imaging with Antibody H131, H131-F(ab')2 and H131-Fab.

Targeting the EphB4 Receptor for Cancer Diagnosis and Therapy Monitoring.

PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.

In vivo small-animal PET/CT of EphB4 receptors using64Cu-labeled peptide

SPECT Imaging of Neuropilin Receptor Type-1 Expression with 131I-Labeled Monoclonal Antibody.

Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts.

EphB4-binding peptide for dual modality {micro}PET/CT and optical imaging of glioblastoma in orthotopic xenograft models

Production of 64Cu-labeled monobody for imaging of human EphA2-expressing tumors

Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates

Evaluation of a Novel EphA2 Targeting Peptide for Triple Negative Breast Cancer Based on Radionuclide Molecular Imaging

Advance of molecular imaging probes targeted for EphB4 receptor

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Axl-Targeted Cancer Imaging with Humanized Antibody h173

Radioiodination, Purification, and Evaluation of Antihuman Tumor-Derived Immunoglobulin G Light Chain Monoclonal Antibody in Tumor-Bearing Nude Mice.

Dual-Modality Micro-Positron Emission Tomography/Computed Tomography and Near-Infrared Fluorescence Imaging of EphB4 in Orthotopic Glioblastoma Xenograft Models

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

131I-Labeled Monoclonal Antibody Targeting Neuropilin Receptor Type-2 for Tumor SPECT Imaging.

Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Positive Tumor with a 64cu Labeled Affibody Protein

Generation and Screening of Monoclonal Antibodies for Immunopet of Epha2 in Cancer

PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.